Our Science – Day Website
Chi-Ping Day, Ph.D.
 |
 |
|
||||||||||||||||||||
Biography
Dr. Chi-Ping Day received his BS diploma in chemistry from National Cheng-Kung University, Tainan, Taiwan in 1992 and MS diploma in biochemistry from National Yang-Ming University, Taipei, Taiwan in 1996. He then joined the Graduate School of Biomedical Sciences at the University of Texas Health Science Center at Houston and M. D. Anderson Cancer Center, where he received his Ph.D. in 2005 for his work on the development of breast cancer-specific gene therapy system. In October 2005, he joined the laboratory of Dr. Merlino as a visiting fellow to receive his post-doctoral training, then became Staff Scientist in 2012.Research
Dr. Day's research focuses on the development of transgenic and preclinical models of recurrent and metastatic diseases, and identification of therapeutic targets of metastatic melanoma.
Selected Publication:
1.Day CP, Carter J, Bonomi C, Hollingshead M, Merlino G. (2012) Preclinical therapeutic response of residual metastatic diseases is distinctive from primary tumor of origin. Int. J. Cancer 130(1):190
2. Day CP, Carter J, Bonomi C, Esposito D, Crise B, Ortiz-Conde B, Hollingshead M, Merlino G. (2009) Lentivirus-mediated bifunctional cell labeling for in vivo melanoma study. Pigment Cell Melanoma Res. 22(3):283-95.
3. Zaidi MR*, Day CP*, Merlino G. (2008) From UVs to metastases: modeling melanoma initiation and progression in the mouse. J. Invest. Dermatol. 128:2381-91. (*equal contribution)
Invention:
1. 'Lentiviral vectors for long term in vivo expression of dual fluorescence/luminescence reporters' (2011) Inventors: Dominic Esposito, Chi-Ping Day, and Glenn Merlino. NIH Employee Invention Report Reference No. E‐132‐2011.
2.'A bioimaging marker‐tolerant mouse allowing consistent tumor labeling and monitoring in an immunocompetent mouse model' (2010) Inventors: Chi-Ping Day and Glenn Merlino. NIH Employee Invention Report Reference No. E‐173‐2010.
This page was last updated on 2/21/2013.
